preterm birth risk diagnostic test  (Sera Prognostics)

Journal: Obstetrics and Gynecology

Article Title: Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

doi: 10.1097/AOG.0000000000005817

Figure Lengend Snippet: Characteristics of Pregnant Participants With Preterm and Term Deliveries

Article Snippet: The overall preterm birth rate in MATISSE was lower than background rates in countries with sufficient participant–event numbers enabling interpretation (Argentina, Japan, South Africa, United States); for example, in South Africa, the RSVpreF group preterm birth rate was 8.3% compared with the national estimate of 13%.

Techniques:

Journal: Obstetrics and Gynecology

Article Title: Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

doi: 10.1097/AOG.0000000000005817

Figure Lengend Snippet: Cumulative distribution, case counts, and cumulative case counts of gestational age at birth among newborns and infants born at less than 37 weeks of gestation. RSVpreF, respiratory syncytial virus prefusion F protein–based vaccine.

Article Snippet: The overall preterm birth rate in MATISSE was lower than background rates in countries with sufficient participant–event numbers enabling interpretation (Argentina, Japan, South Africa, United States); for example, in South Africa, the RSVpreF group preterm birth rate was 8.3% compared with the national estimate of 13%.

Techniques: Virus

Journal: Obstetrics and Gynecology

Article Title: Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

doi: 10.1097/AOG.0000000000005817

Figure Lengend Snippet: Relative risk for newborn and infant outcomes ( A ) and newborn and infant deaths during the study ( B ). Shown are data from the newborn and infant safety population. Serious adverse event (SAE)–related hospitalizations were within the neonatal period (ie, 4 weeks). Low Apgar scores were a first score lower than 4 or last score lower than 7. AE, adverse event; RSVpreF, respiratory syncytial virus prefusion F protein–based vaccine.

Article Snippet: The overall preterm birth rate in MATISSE was lower than background rates in countries with sufficient participant–event numbers enabling interpretation (Argentina, Japan, South Africa, United States); for example, in South Africa, the RSVpreF group preterm birth rate was 8.3% compared with the national estimate of 13%.

Techniques: Virus

Journal: Obstetrics and Gynecology

Article Title: Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

doi: 10.1097/AOG.0000000000005817

Figure Lengend Snippet: Preterm births by gestational age (GA) at vaccination. Shown are data from the infant safety population. Numbers above the error bars are the preterm birth rate (less than 37 weeks of gestation) overall and by GA at vaccination. Also shown is the relative risk (95% CI). In the overall and less than 28 weeks of gestation at vaccination groups, the rate of GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in both the respiratory syncytial virus prefusion F protein–based vaccine (RSVpreF) and placebo groups.

Article Snippet: The overall preterm birth rate in MATISSE was lower than background rates in countries with sufficient participant–event numbers enabling interpretation (Argentina, Japan, South Africa, United States); for example, in South Africa, the RSVpreF group preterm birth rate was 8.3% compared with the national estimate of 13%.

Techniques: Virus

Journal: Obstetrics and Gynecology

Article Title: Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

doi: 10.1097/AOG.0000000000005817

Figure Lengend Snippet: Preterm births by income region ( A ) and relative risk for preterm birth overall and by country ( B ). Shown are data from the newborn and infant safety population. A. Numbers above the bars are the preterm birth rate (less than 37 weeks of gestational age [GA]) overall and by World Bank income region. Also shown is the relative risk (95% CI). In the overall group, the rate of GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in both the respiratory syncytial virus prefusion F protein–based vaccine (RSVpreF) and placebo groups. In the high-income group, the preterm birth rate at a GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in the placebo group. In the non–high-income group, the preterm birth rate at a GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in the RSVpreF group. In the upper-middle–income group, the preterm birth rate at a GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in the RSVpreF group. B. Countries with more than five preterm births overall. Countries included in each income region are summarized in Appendix 2, available online at http://links.lww.com/AOG/D944 . n, number of newborns and infants born preterm; N, total number of infants.

Article Snippet: The overall preterm birth rate in MATISSE was lower than background rates in countries with sufficient participant–event numbers enabling interpretation (Argentina, Japan, South Africa, United States); for example, in South Africa, the RSVpreF group preterm birth rate was 8.3% compared with the national estimate of 13%.

Techniques: Virus